Premium
PTC Therapeutics Inc (PTCT)
NASDAQ
Hot Features
Inscrivez-vous gratuitement pour obtenir des cotations en temps réel, des graphiques interactifs, un flux d'options en direct et plus encore.
| Date | Nom du détenteur | Actions transigées | Fourchette de valeur ($) | Type d'opération | Fourchette de prix ($) | Actions en fin de déclaration | % de variation |
|---|---|---|---|---|---|---|---|
| 2026-05-15 | Mr. Mark Elliott BouldingExec. VP & Chief Legal Officer | -2,81k | 130,72k | Derivative Exercise and Sale | 25,69 - 72,67 | 105,21k | - |
| 2026-05-14 | Dr. Matthew B. KleinCEO & Director | -12,57k | 917,15k | Vente | 72,46 - 73,08 | 116,19k | -9,76% |
| 2026-05-08 | Mr. Mark Elliott BouldingExec. VP & Chief Legal Officer | -3,54k | 114,82k | Derivative Exercise and Sale | 46,54 - 79,31 | 105,21k | - |
| 2026-04-06 | Mr. Mark Elliott BouldingExec. VP & Chief Legal Officer | -2,27k | 68,01k | Derivative Exercise and Sale | 39,42 - 69,75 | 105,21k | - |
| 2026-04-02 | Dr. Lee Scott GoldenExec. VP & Chief Medical Officer | -829,00 | 56,36k | Vente | 67,99 | 28,51k | -2,83% |
| 2026-04-01 | Dr. Neil AlmsteadChief Technical Operations Officer | -52,00k | 3,59M | Automatic Disposition | 68,89 - 70,30 | 15,71k | -76,80% |
| 2026-03-12 | Dr. Matthew B. KleinCEO & Director | -2,66k | 170,58k | Vente | 64,08 | 125,11k | -2,08% |
| 2026-03-10 | Ms. Stephanie Smith OkeyIndependent Director | -15,17k | 551,62k | Derivative Exercise and Sale | 33,63 - 70,00 | 5,67k | - |
| 2026-03-05 | Dr. Neil AlmsteadChief Technical Operations Officer | -3,99k | 252,82k | Automatic Disposition | 63,38 | 67,71k | -5,56% |
| 2026-03-05 | Dr. Lee Scott GoldenExec. VP & Chief Medical Officer | -10,00k | 633,80k | Automatic Disposition | 63,38 | 28,03k | -26,29% |
| 2026-03-05 | Ms. Stephanie Smith OkeyIndependent Director | -6,33k | 401,39k | Automatic Disposition | 63,38 | 5,67k | -52,78% |
| 2026-02-19 | Mr. Mark Elliott BouldingExec. VP & Chief Legal Officer | -3,02k | 209,76k | Automatic Disposition | 68,54 - 69,82 | 105,21k | -2,79% |
| 2026-02-18 | Dr. Neil AlmsteadChief Technical Operations Officer | -3,12k | 216,47k | Vente | 69,36 | 71,70k | -4,17% |
| 2026-02-18 | Mr. Eric PauwelsChief Business Officer | -3,02k | 209,40k | Vente | 69,36 | 25,12k | -10,73% |
| 2026-02-18 | Mr. Pierre GravierCFO | -2,99k | 207,53k | Vente | 69,36 | 27,94k | -9,67% |
| 2026-02-18 | Dr. Lee Scott GoldenExec. VP & Chief Medical Officer | -2,48k | 172,29k | Vente | 69,36 | 52,38k | -4,53% |
| 2026-02-18 | Ms. Christine UtterSenior VP, CAO & Head of People Services | -2,49k | 172,98k | Vente | 69,36 | 39,45k | -5,95% |
| 2026-02-18 | Dr. Matthew B. KleinCEO & Director | -7,37k | 511,25k | Vente | 69,36 | 121,77k | -5,71% |
| 2026-02-17 | Mr. Mark Elliott BouldingExec. VP & Chief Legal Officer | -2,81k | 122,65k | Derivative Exercise and Sale | 25,69 - 70,13 | 64,48k | - |
| 2026-02-18 | Mr. Mark Elliott BouldingExec. VP & Chief Legal Officer | -3,08k | 213,70k | Vente | 69,36 | 64,48k | -4,56% |
| 2026-01-08 | Dr. Neil AlmsteadChief Technical Operations Officer | -940,00 | 71,86k | Vente | 76,45 | 72,41k | -1,28% |
| 2026-01-08 | Mr. Mark Elliott BouldingExec. VP & Chief Legal Officer | -1,29k | 98,31k | Vente | 76,45 | 66,61k | -1,89% |
| 2026-01-08 | Mr. Mark Elliott BouldingExec. VP & Chief Legal Officer | -5,06k | 390,77k | Automatic Disposition | 76,56 - 79,52 | 66,61k | -7,06% |
| 2026-01-08 | Mr. Eric PauwelsChief Business Officer | -1,45k | 111,16k | Vente | 76,45 | 27,29k | -5,06% |
| 2026-01-08 | Mr. Eric PauwelsChief Business Officer | -5,89k | 454,79k | Automatic Disposition | 76,42 - 78,70 | 27,29k | -17,76% |
| 2026-01-08 | Dr. Lee Scott GoldenExec. VP & Chief Medical Officer | -866,00 | 66,21k | Vente | 76,45 | 39,65k | -2,14% |
| 2026-01-08 | Dr. Matthew B. KleinCEO & Director | -2,51k | 192,20k | Vente | 76,45 | 106,39k | -2,31% |
| 2026-01-08 | Ms. Christine UtterSenior VP, CAO & Head of People Services | -1,03k | 79,05k | Vente | 76,45 | 37,59k | -2,68% |
| 2026-01-06 | Ms. Christine UtterSenior VP, CAO & Head of People Services | -2,62k | 201,92k | Vente | 76,95 - 77,45 | 38,63k | -6,34% |
| 2026-01-06 | Dr. Neil AlmsteadChief Technical Operations Officer | -2,41k | 186,10k | Vente | 76,95 - 77,48 | 73,35k | -3,18% |
| 2026-01-06 | Mr. Eric PauwelsChief Business Officer | -3,14k | 242,42k | Vente | 76,95 - 77,48 | 34,64k | -8,31% |
| 2026-01-06 | Dr. Lee Scott GoldenExec. VP & Chief Medical Officer | -1,98k | 152,86k | Vente | 76,95 - 77,48 | 40,51k | -4,66% |
| 2026-01-06 | Dr. Matthew B. KleinCEO & Director | -8,17k | 629,90k | Vente | 76,95 - 77,48 | 108,90k | -6,97% |
| 2026-01-06 | Mr. Pierre GravierCFO | -2,14k | 164,60k | Vente | 76,95 | 24,64k | -7,99% |
| 2026-01-07 | Mr. Mark Elliott BouldingExec. VP & Chief Legal Officer | -3,38k | 132,75k | Derivative Exercise and Sale | 38,10 - 78,98 | 72,96k | - |
| 2026-01-06 | Mr. Mark Elliott BouldingExec. VP & Chief Legal Officer | -3,24k | 250,27k | Vente | 76,95 - 77,48 | 72,96k | -4,25% |
| 2026-01-05 | Mr. Mark Elliott BouldingExec. VP & Chief Legal Officer | -2,27k | 81,87k | Derivative Exercise and Sale | 39,42 - 76,79 | 67,45k | - |
| 2026-01-05 | Ms. Emma ReeveIndependent Director | -734,00 | 21,62k | Derivative Exercise and Sale | 46,54 - 76,00 | 6,67k | - |
| 2026-01-02 | Dr. Glenn Daniel SteeleIndependent Director | -12,00k | 545,88k | Derivative Exercise and Sale | 30,86 - 76,35 | 16,17k | - |
| 2025-12-30 | Dr. Matthew B. KleinCEO & Director | -8,09k | 619,94k | Vente | 76,64 | 92,81k | -8,02% |
| 2025-12-19 | Mr. Eric PauwelsChief Business Officer | -20,51k | 248,16k | Derivative Exercise and Sale | 18,01 - 78,43 | 17,52k | - |
| 2025-12-17 | Mr. Eric PauwelsChief Business Officer | -43,49k | 578,26k | Derivative Exercise and Sale | 18,01 - 76,00 | 17,52k | - |
| 2025-12-16 | Mr. Michael SchmertzlerIndependent Chairman of the Board | 24,00k | 740,64k | Derivative Exercise and Retained Stock | 30,86 | 1,54M | 1,59% |
| 2025-12-03 | Ms. Emma ReeveIndependent Director | -733,00 | 23,51k | Derivative Exercise and Sale | 46,54 - 78,62 | 4,33k | - |
| 2025-12-02 | Dr. Matthew B. KleinCEO & Director | -3,43k | 271,05k | Vente | 79,07 | 82,15k | -4,01% |
| 2025-11-24 | Dr. Neil AlmsteadChief Technical Operations Officer | -107,50k | 5,57M | Derivative Exercise and Sale | 18,01 - 85,37 | 56,54k | - |
| 2025-11-24 | Dr. Allan Steven JacobsonCo-Founder & Independent Director | -26,00k | 1,75M | Derivative Exercise and Sale | 11,23 - 85,32 | 15,12k | - |
| 2025-11-21 | Ms. Emma ReeveIndependent Director | -10,00k | 283,40k | Derivative Exercise and Sale | 51,16 - 79,50 | 4,33k | - |
| 2025-11-20 | Ms. Stephanie Smith OkeyIndependent Director | -867,00 | 0,00 | Other Disposition | - | 5,67k | -13,27% |
| 2025-11-17 | Mr. Mark Elliott BouldingExec. VP & Chief Legal Officer | -2,81k | 141,45k | Derivative Exercise and Sale | 25,69 - 77,18 | 103,90k | - |
| 2025-11-12 | Ms. Emma ReeveIndependent Director | -7,33k | 205,03k | Derivative Exercise and Sale | 46,54 - 74,50 | 4,33k | - |
| 2025-10-30 | Ms. Emma ReeveIndependent Director | -12,00k | 376,80k | Derivative Exercise and Sale | 38,10 - 69,50 | 4,33k | - |
| 2025-10-30 | Ms. Emma ReeveIndependent Director | -3,67k | 254,79k | Automatic Disposition | 69,50 | 4,33k | -45,83% |
| 2025-10-07 | Mr. Mark Elliott BouldingExec. VP & Chief Legal Officer | -3,38k | 85,50k | Derivative Exercise and Sale | 38,10 - 64,97 | 103,90k | - |
| 2025-10-03 | Mr. Mark Elliott BouldingExec. VP & Chief Legal Officer | -24,92k | 656,16k | Derivative Exercise and Sale | 39,42 - 67,15 | 103,90k | - |
| 2025-10-03 | Dr. Neil AlmsteadChief Technical Operations Officer | -55,00k | 1,94M | Derivative Exercise and Sale | 30,86 - 67,16 | 56,54k | - |
| 2025-10-03 | Dr. Allan Steven JacobsonCo-Founder & Independent Director | -12,00k | 409,68k | Derivative Exercise and Sale | 30,86 - 65,00 | 15,12k | - |
| 2025-10-03 | Ms. Emma ReeveIndependent Director | -25,56k | 772,69k | Derivative Exercise and Sale | 33,02 - 66,93 | 8,00k | - |
| 2025-09-11 | Ms. Emma ReeveIndependent Director | -10,84k | 359,75k | Derivative Exercise and Sale | 25,69 - 59,50 | 8,00k | - |
| 2025-09-11 | Ms. Emma ReeveIndependent Director | -4,87k | 289,65k | Automatic Disposition | 59,50 | 8,00k | -37,83% |
| 2025-09-11 | Mr. Mark Elliott BouldingExec. VP & Chief Legal Officer | -47,25k | 1,09M | Derivative Exercise and Sale | 38,10 - 62,09 | 103,90k | - |
| 2025-09-09 | Mr. David P. SouthwellIndependent Director | -12,00k | 329,76k | Derivative Exercise and Sale | 30,86 - 58,34 | 14,52k | - |
| 2025-09-08 | Mr. Eric PauwelsChief Business Officer | -39,85k | 1,36M | Derivative Exercise and Sale | 11,23 - 56,94 | 20,06k | - |
| 2025-08-28 | Dr. Allan Steven JacobsonCo-Founder & Independent Director | -1,67k | 83,60k | Vente | 50,15 | 15,12k | -9,93% |
| 2025-08-15 | Mr. Mark Elliott BouldingExec. VP & Chief Legal Officer | -2,81k | 64,39k | Derivative Exercise and Sale | 25,69 - 48,58 | 103,90k | - |
| 2025-08-05 | Dr. Matthew B. KleinCEO & Director | -10,74k | 555,64k | Vente | 51,74 | 77,77k | -12,13% |
| 2025-07-15 | Mr. Pierre GravierCFO | -2,52k | 124,44k | Vente | 49,46 | 20,62k | -10,87% |
Les dernières valeurs consultées apparaîtront dans cette boîte, vous permettant de choisir facilement les titres vus auparavant.
Assistance: support@advfn.fr
En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales
S'inscrire avec l'e-mail
Vous avez déjà un compte? Connexion
Vous n'avez pas de compte ? Inscription
En m'inscrivant, je confirme avoir lu, compris et accepté les Conditions générales d'ADVFN et j'affirme etre un investisseur privé.
